Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corcept Therapeutics Inc. (CORT) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-powered summaries that help explain their contents. Corcept is a Nasdaq-listed, commercial-stage pharmaceutical company focused on cortisol modulation in endocrinologic, oncologic, metabolic and neurologic disorders, and its filings offer detailed insight into this business.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Corcept describes its commercial activities with Korlym, which it identifies as the first FDA-approved medication for patients with endogenous hypercortisolism, as well as its research and development programs in hypercortisolism, solid tumors, ALS and liver disease. These periodic reports typically discuss product revenue, research and development spending, and risks related to drug development and regulation.
Current reports on Form 8-K, some of which are summarized in the data provided, disclose material events such as quarterly financial results, submission and FDA acceptance of New Drug Applications for relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application to the European Medicines Agency, and the receipt of an FDA Complete Response Letter for relacorilant in hypertension secondary to hypercortisolism. Other 8-K filings describe corporate developments, including changes to distribution agreements for Korlym and board-level changes accompanied by consulting arrangements.
On this page, users can review Corcept’s Forms 10-K, 10-Q and 8-K as they are made available from EDGAR, while AI-generated highlights point out key topics such as clinical trial updates, regulatory milestones, revenue trends and significant contracts. The filings section also surfaces exhibits referenced in 8-Ks, helping investors and researchers understand how Corcept’s cortisol-modulation strategy, pipeline progress and commercial operations are reflected in its official regulatory reporting.
Corcept Therapeutics Inc. reported a Rule 144 notice for the proposed sale of 20,000 common shares through Stifel Nicolaus & Company Inc. on
The notice also discloses multiple sales by the same person, William Guyer, over the past three months: 4,379, 500, 14, 35,007, and 20,000 shares on dates from
Corcept Therapeutics Incorporated reported that board member Gillian Cannon, Ph.D. has resigned from its Board of Directors, effective October 10, 2025. The company states that Dr. Cannon did not resign because of any disagreement regarding its operations, financial statements, policies or practices, indicating this is a non-controversial transition.
Corcept has entered into a Consulting Services Agreement with Dr. Cannon, effective as of her resignation date, under which she will provide consulting services to the Board until the company’s 2026 stockholder meeting. As compensation, she will receive a cash fee of $5,708.33 per month, and her previously granted, outstanding stock options will continue to vest on their original schedules during the consulting term.
Corcept Therapeutics (CORT) CEO and Director Joseph K. Belanoff reported insider stock sales on October 1, 2025 executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
Sales were reported in three tranches of 5,616, 31,190, and 3,194 common shares at weighted average prices of $84.2895, $85.164, and $85.6662, respectively. The filing notes price ranges for each tranche and that detailed breakdowns are available from the issuer upon request.
Following these transactions, indirect holdings stood at 2,781,370 shares in the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, over which the reporting person has voting power and disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics (CORT) insider transaction: On 10/01/2025, an officer exercised 5,000 stock options at an exercise price of $13.56 per share and acquired 5,000 common shares. The same day, the officer sold a total of 5,000 shares in three trades executed under a Rule 10b5-1 plan adopted on August 30, 2024: 927 shares at $83.7111, 3,473 shares at $84.9217, and 600 shares at $85.3875.
Following these transactions, the officer beneficially owned 10,277 common shares. Footnotes state this figure includes unvested restricted stock awards granted on December 2, 2024; March 3, 2025; June 2, 2025; and September 2, 2025, which vest one year from their grant dates if conditions are met. The officer also held 21,571 derivative securities (stock options) after the reported activity, with the exercised option series expiring on 02/07/2030.
Corcept Therapeutics (CORT) insider activity: President Sean Maduck reported option exercises and open‑market sales on 10/01/2025 under a Rule 10b5‑1 plan. He exercised 1,986 stock options at $5.05 and 18,014 at $8.27, then sold 959 shares at a weighted average price of $83.7344, 16,394 at $85.0562, and 2,647 at $85.5758.
Following these transactions, direct holdings were 7,904 shares. Indirect holdings were 59,717 shares held by the Sean and Molly Maduck Living Trust, 40,000 by the SNM 2025 Grantor Retained Annuity Trust, and 10,000 by Duckhill Capital, LLC.
In Table II, the $5.05 option was fully exercised with 0 remaining, and 281,986 options at an exercise price of $8.27 remain outstanding, fully exercisable and expiring on 02/10/2027.
Form 144 notice for Corcept Therapeutics, Inc. (CORT) reports a proposed sale of 40,000 common shares acquired by stock option exercise on 07/06/2022. The sale is to be effected through Stifel Nicolaus & Company Inc. on or about 10/01/2025 with an aggregate market value listed as $3,324,400. The filing shows the issuer's outstanding shares at 105,370,000. The seller appears in recent sale history as Joseph Belanoff, who sold 615 shares on 07/17/2025 for $45,318, 40,000 shares on 08/04/2025 for $2,742,006, and 40,000 shares on 09/02/2025 for $2,821,034. The filer certifies no undisclosed material nonpublic information and provides standard signature/representation language.
Corcept Therapeutics (CORT) insider filing under Rule 144 reports a proposed sale of 20,000 common shares through Stifel Nicolaus & Co., with an aggregate market value of $1,662,200 and an approximate sale date of 10/01/2025. The filing states the 20,000 shares were acquired via a stock option exercise and paid in cash on 10/01/2025. The filer also disclosed multiple prior open-market sales by the same person over the past three months totaling 62,000 shares with gross proceeds reported for each trade. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
CORCEPT THERAPEUTICS INC (CORT) Form 144 filing reports a proposed sale of 5,000 common shares through Stifel Nicolaus & Co. with an aggregate market value of $415,550.00, planned for 10/01/2025 on NASDAQ. The filing states these 5,000 shares were acquired the same day (10/01/2025) by stock option exercise and paid in cash.
The filing also lists prior sales by the same person, Joseph D. Lyon, totaling 15,000 shares sold on 07/01/2025, 07/17/2025, 07/18/2025, 08/01/2025, and 09/02/2025 with reported gross proceeds for each transaction. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), reported a transaction dated 09/19/2025. The Form 4 shows a disposition of 200 shares of Common Stock coded as G(1) at a price of $0, with an explanatory note that the shares were donated to a Fidelity Charitable Giving Account. Following the reported transaction, the reporting person beneficially owned 5,287 shares. The form is signed by an attorney-in-fact and cites a power of attorney on file with the SEC.
Gillian M. Cannon, a director of Corcept Therapeutics Inc. (CORT), reported a donation of 7,393 shares of the issuer's common stock executed on 09/10/2025 under transaction code G(1). The filing shows the shares were donated to a Fidelity Charitable Giving Account and the reporting person’s beneficial ownership of common stock following the transaction is reported as 0 shares. The Form 4 was signed by an attorney-in-fact, Joseph Douglas Lyon, on 09/11/2025. The filing includes a remark that the power of attorney is on file with the SEC.